Correlation Between Rapport Therapeutics, and Unitronix

Can any of the company-specific risk be diversified away by investing in both Rapport Therapeutics, and Unitronix at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Rapport Therapeutics, and Unitronix into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Rapport Therapeutics, Common and Unitronix, you can compare the effects of market volatilities on Rapport Therapeutics, and Unitronix and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Rapport Therapeutics, with a short position of Unitronix. Check out your portfolio center. Please also check ongoing floating volatility patterns of Rapport Therapeutics, and Unitronix.

Diversification Opportunities for Rapport Therapeutics, and Unitronix

-0.41

Correlation Coefficient

Rapport Therapeutics,  Unitronix

Very good diversification

The 3 months correlation between Rapport and Unitronix is -0.41. Overlapping area represents the amount of risk that can be diversified away by holding Rapport Therapeutics, Common and Unitronix in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Unitronix and Rapport Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Rapport Therapeutics, Common are associated (or correlated) with Unitronix. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Unitronix has no effect on the direction of Rapport Therapeutics, i.e., Rapport Therapeutics, and Unitronix go up and down completely randomly.

Pair Corralation between Rapport Therapeutics, and Unitronix

Given the investment horizon of 90 days Rapport Therapeutics, Common is expected to generate 1.28 times more return on investment than Unitronix. However, Rapport Therapeutics, is 1.28 times more volatile than Unitronix. It trades about 0.11 of its potential returns per unit of risk. Unitronix is currently generating about -0.12 per unit of risk. If you would invest  1,463  in Rapport Therapeutics, Common on August 24, 2025 and sell it today you would earn a total of  1,262  from holding Rapport Therapeutics, Common or generate 86.26% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Rapport Therapeutics, Common  vs.  Unitronix

Rapport Therapeutics,

Risk-Adjusted Performance

Fair

Compared to the overall equity markets, risk-adjusted returns on investments in Rapport Therapeutics, Common are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Rapport Therapeutics, reported solid returns over the last few months and may actually be approaching a breakup point.

Unitronix

Risk-Adjusted Performance

Weakest

Over the last 90 days Unitronix has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Rapport Therapeutics, and Unitronix

The main advantage of trading using opposite Rapport Therapeutics, and Unitronix positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Rapport Therapeutics, position performs unexpectedly, Unitronix can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Unitronix will offset losses from the drop in Unitronix's long position.

The idea behind Rapport Therapeutics, Common and Unitronix pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.